Solid Biosciences Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Percent
Solid Biosciences Inc. (SLDB) reported Effective Income Tax Rate Reconciliation, Tax Credit, Percent of -6.30% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits · last filed 2025-03-06
- Solid Biosciences Inc. effective income tax rate reconciliation, tax credit, percent for the quarter ending 2018-03-31 was -6.40%.
- Solid Biosciences Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2024 was -6.30%.
- Solid Biosciences Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2023 was -7.00%, a 160.87% decline from fiscal 2022.
- Solid Biosciences Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2022 was 11.50%, a 4.96% decline from fiscal 2021.
- Solid Biosciences Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2021 was 12.10%.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 3 month | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 6 month | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 9 month | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | -6.30% 10-K · filed 2025-03-06 | ||||
| 2023-12-31 | -7.00% 10-K · filed 2025-03-06 | 7.00% 10-K · filed 2024-03-13 | |||
| 2022-12-31 | 11.50% 10-K · filed 2024-03-13 | ||||
| 2021-12-31 | 12.10% 10-K · filed 2023-03-23 | -12.10% 10-K · filed 2022-03-14 | |||
| 2020-12-31 | -9.60% 10-K · filed 2022-03-14 | ||||
| 2019-12-31 | -10.90% 10-K · filed 2021-03-15 | ||||
| 2018-12-31 | -9.20% 10-K · filed 2020-03-12 | ||||
| 2018-09-30 | -10.30% 10-Q · filed 2018-11-13 | ||||
| 2018-06-30 | -9.50% 10-Q · filed 2018-08-10 | ||||
| 2018-03-31 | -6.40% 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |